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Tardive dyskinesia (TD) is a syndrome 
manifesting in abnormal involuntary move-
ments following prolonged exposure to neuro-
leptic treatment and the syndrome may be 
irreversible. This syndrome was initially 
described by Hall et al. (1956), Schonecker 
et al. (1957) and Sigwald et al. (1959). 
Clinically, this syndrome includes a 
variety of hyperkinetic involuntary move-
ments primarily of the tongue, mouth and 
face even though other parts can be affected. 
These movements are chorieform, coordi-
nated, involuntary, stereotyped and rhyth-
mic. They continue as long as there are 
no internal or external events to disturb 
them. Generally, onset of these symptoms 
is gradual as in the unfolding of a flower 
and not dramatic as in dystonia. TD is 
greatly increased by anxiety or heightened 
vigilance and completely disappears during 
sleep. Any behavior that increases asso-
ciated movements will enhance TD. Thus, 
an asymptomatic patient may manifest 
dyskinesia of his hands and fingers when 
his arms swing while walking. The abnormal 
movements disappear in areas directly in-
volved in a voluntary activity as noticed 
by the cessation of buccal movements while 
talking and of the finger movements while 
writing. On the other hand, dyskinesia 
js enhanced in areas other than those of 
voluntary activity. Involuntary movements 
are more pronounced in a standing than in 
a sitting or supine position. Generally, it 
has been noted that patients are unaware 
of and not disturbed by these movements 
(Ayd, 1970) but this is far from universal 
(Uhrbrand and Faurbye, 1960). While this 
is true in older chronically institutionalized 
patients, younger patients do feel em-
barassed and uncomfortable. It is also 
stated that respiration, mastication or speech 
are not affected which is generally true. 
However, gruntling vocalizations, jerky res-
pirations and oral ulcerations are noted 
in some. Alertness and intelligence are not 
affected. 
Oral facial dyskinesia is the charac-
teristic feature of this syndrome. Initial 
symptoms include mild forward backward 
or lateral movements of the tongue (Ayd, 
1967). Later, more obvious twisting and 
protruding movements of the tongue, pout-
ing and sucking movements of the lips, 
and various chewing movements of the 
mouth develop. Even though the upper 
portion of the face is generally spared 
(Degkwitz, 1969), frequent blinking, ble-
pharospasm and arching of the eyebrows 
may occur. While orofacial dyskinesia is 
common and is the first to appear in older 
patients, abnormal movements of the ex-
tremities and trunk are more common in 
young individuals (Ayd, 1970 ; Degkwitz, 
1969). In addition, in advanced cases, 
chorieform movements and distal athetosis 
of limbs and tapping motions of the feet 
are noted. Postural and gait disturbances 
include exaggerated lordosis, rocking and 
swaying, shoulder shrugging and rotary 
pelvic movements. Lipper (1973) noted 
impaired or absent optokinetic nystagmus 
more frequently among the TD patients 
than among nondyskinetic control group. 
However, in parkinsonian patients as well, 
optokinetic nystagmus is decreased. 
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Most often, the insidous development 
of dyskinesia is noted by the relatives or the 
physician of the patient while the patient is 
still on antipsychotic drugs (Degkwitz, 1969). 
It may also manifest after a reduction in 
dosage or discontinuation of neuroleptic 
medication (Degwitz and Wenzel 1967). 
This indicates that parkinsonian symptoms 
may mask the signs and even delay the 
recognition of the TD. In some cases, 
transient dyskinesias occur which last for 
only a few days (McAndrew et al, 1972). 
Even after discontinuation of antipsychotic 
drugs, the irreversibility of some of the late 
drug-induced dyskinesia is well established 
(Crane, 1973) in spite of occasional reports 
to the confary (Kline, 1968). Prognostic 
indicators for recovery are not currently 
available. Long-term studies suggest that 
once dyskinesia occurs, it is either static 
or gradually improves. 
Varieties of tardive dyskinesia : Apart 
from the dyskinetic syndromes resulting 
from various neurological disorders includ-
ing Huntington's chorea and psychiatric 
syndromes including motility disorders of 
schizophrenia, spontaneous dyskinesias occur 
in elderly patients. Clinically, while adults 
generally manifest orofacial dyskinesia child-
ren manifest dyskinesia of the extremities. 
Villeneuve (1972) has described a clinical 
syndrome with rapid, chewing-like move-
ments of a rabbit's mouth which he labelled 
as "Rabbits Syndrome". In this syndrome, 
he noted that the tongue was not involved. 
On the basis of pharmacological response, 
Casey (1976) speculates that physostigmine 
responsive group who improve with deanol 
may be different from hyperdopaminergic 
group. However, the existence of sub-
groups and their significance need to be 
proven. 
Predisposing Factors 
Older patients have been noted to be 
more susceptible (Crane and Smeets, 1974; 
Just et al., 1976). In one study, it was 
reported that while only two percent of the 
geriatric patients not receiving the drugs 
had signs of TD, there was a twenty times 
greater prevalence (40 percent) among drug-
treated patients (Greenblatt et al., 1968). 
However, some epidemiological studies 
Kennedy et al., 1971) do not implicate age 
while others report that advanced age is re-
lated toTD(Faurbye etal., 1964 ; Brandon 
et al., 1971). These contradictory findings 
can be explained by the complex charac-
teristics of the chronically treated patient 
population. The relationship of age and 
TD may be linked closely with the duration 
of drug intake whereby the elderly may 
receive drugs for a longer duration. The 
earlier reports of an association between 
brain damage and TD (Druckman et al., 
1962 ; Faurbye et al. 1964) have been 
contradicted by the more recent workers 
(Degkwitz and Wenzel 1967 ; Brandon 
et al., 1971 ; Gelenberg 1976). These find-
ings are in conformity with the clinical 
observation that TD may occur in patients 
without any detectable organicity. Even 
though organicity may enhance suscept-
ibility, it is not a prerequisite for the deve-
lopment of TD. Similarly, association 
between female sex and TD have been 
claimed by some (Hunter et al., 1964, And 
1967, Kennedy et al, 1971) and not by 
others (Degkwite and Weneel, 1967; Fann, 
et al, 1972; Crane, 1970). Some have noted 
no correlation between earlier dystonia and 
later TD (Klawans, 1973). The relation-
ship between severe early onset of parkin-
sonian symptoms and TD is interesting. 
Crane (1972) has suggested that patients 
exhibiting significant drug-induced parkin-
sonism are predisposed to TD. Further 
evidence for this is provided by our own 
study (Pandurangi et al., 1977) which re-
vealed that the TD group had received 
anticholinergic drugs more often and in 
higher doses than the matched control group. 
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may be related to early onset of drug-
induced extra-pyramidal symptoms. At 
present, there is no evidence that the under-
lying psychiatric illness plays any role in 
predisposition. The majority of reports 
indicate that TD occurs in all patients who 
are on prolonged neuroleptic therapy in-
cluding schizophrenia, prolonged affective 
illness and chronic organic brain syndrome 
(Jus etal. 1976 ; Brandon et al., 1971 ; Crane 
and Smeets, 1974). However, Simpson 
(1973) reported manic depressive patients 
developed TD more often than schizophrenic 
patients indicating that schizophrenics were 
less susceptible. But this conclusion was 
based on clinical observation only. TD is 
also reported to occur in various neurotic 
as well as medically ill patients who receive 
neuroleptic treatment (Faurbye et al. 1964 ; 
Evans 1965 ; Klawans et al. 1974). Kunin 
(1976) has reported a deficiency of manga-
nese in TD and its improvement with this 
mineral supplement. Thus, it appears that 
neuroleptics can induce TD in susceptible 
patients the nature of which is unknown. 
Prevalence 
The prevalence of TD is difficult to 
estimate. The reported occurrence of 
TD in chronic institutionalized patients 
varies from 0.5 to 56 percent with 
an average of about 15 percent. This wide 
discrepancy may be related to the type of 
patient population, the diagnostic criteria, 
and the assessment procedures. Hoff and 
Hoffman (1967) reported the incidence 
of dyskinesia to be 0.5 percent, Villeneuve 
et al. (1969) and Roxburgh (1970) two 
per cent, Eckman (1968) three percent and 
many others six to 56 percent. Some 
studies show a low incidence as inclusion 
was limited to oral dyskinesias only (Dynes 
1970; Lehmann et al. 1970; Turuner and 
Achte 1967) and others included only the 
most severe cases (Roxburgh, 1970) while 
Villeneuve et al. (1969) collected data on 
the basis of hospital records and question-
naires completed by the ward physicians. 
Among studies reporting a high incidence 
of dyskinesia, Greenblatt et al. (1968) in-
cluded exclusively geriatric patients and 
Kennedy et al. (1971) included patients on 
a high dose of trifluoperazine for a number 
of years. Similarly Crane's (1968 ; 1970) 
subjects were on large doses of chlorpro-
mazine or trifluoperazine. Hippius and 
Lange (1970) and Brandon et al. (1971) 
may have included patients with motor 
disorders unrelated to drugs, thereby con-
tributing to the reported high incidence. 
The same may be true of Fann's (1972) 
study. In the study by Jus et al. (1976) 
the 56 percent incidence may be related 
to the older age of the population and 
employment of polygraphic diagnosis. Of 
great concern is the recent report of a 41 
percent prevalence among out-patients (Asnis 
et al. 1977) as it suggests that high incidence 
of TD is not restricted to institutionalized 
regressed patients. These indicate that 
perhaps only some are susceptible and 
others are relatively immune to the syn-
drome. More important is the fact that 
none of the above mentioned figures represent 
either the incidence or prevalence among a 
given number of stable population but only 
give the number of TD in a residual popula-
tion without indicating the total number in 
the denominator. Thus these are not very 
accurate epidemiological figures. The in-
cidence and prevalence of TD among all 
patients receiving neuroleptics may perhaps 
be as low as not to cause alarm. In one 
such study, six of 90 patients had dyskinesia. 
A clear uniform definition, good assessment 
and prospective study in a sample popu-
lation receiving neuroleptic medication are 
urgently needed. The impression that TD 
is very frequent does not seem to have a 
very convincing foundation at present. 
Precipitating Factors 
Role of medication : Dyskinesia is not 
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receiving neuroleptic drugs. It occurs 
spontaneously (Pakkenberg and Fog, 1974) 
as well in untreated schizophrenic patients 
(Stevens, 1974) and in those with organic 
brain syndromes (Appenzeller and Biehl, 
1968). However, it has been confirmed 
that the incidence o£ TD in patients with 
a history of drug treatment is higher than 
in similar patients not exposed to neuro-
leptic treatment (Greenblatt et al. 1968 ; 
Heinrich et al. 1968 ; Hippius and Lange 
1970 ; and Seide and Muller 1967) while 
only Demers (1966) and Brandon et al. 
(1971) could not find any significant differ-
ence in TD between the two groups. These 
findings indicate that neuroleptics are only 
precipitating factors in the occurrence of 
TD. 
However TD is reported to occur pre-
dominantly in patients who have been on 
neuroleptic medication for prolonged periods 
and in high doses. However, small doses 
for shorter duration do not offer any im-
munity against the occurrence of TD 
(Klawans et al., 1974). Some studies indi-
cate that even though TD can occur spon-
taneously, drug treatment increases the 
susceptibility for this syndrome. Curran 
(1973) and Turek (1975) have with some 
justification argued that a direct relation-
ship between neuroleptic drugs and TD is 
not proven with sufficient evidence on the 
basis that lowering of phenothiazines would 
enhance rather than decrease TD and that 
no knowledge of predisposing factors is 
available. However, both these objections 
do not hold validity as a direct relation can 
exist even when the drug is only a preci-
pitating factor in predisposed individuals 
and that the underlying mechanism of with-
drawal dyskinesia is at least partially elu-
cidated. At present, we do not know 
whether any particular drug is more likely 
to induce TD than other and we do not 
know whether the total amount of medica-
tion given over time or the total amount 
given in any one day has any effect whatever 
on the likelihood that the patient would 
develop TD. All neuroleptic preparations 
including phenothiazines (Crane, 1973), 
butyrophenones (Jacobson et al., 1974), 
reserpine (Degkwitz, 1969; Wolf, 1973) and 
thioxanthines (Ananth and Costin, 1977) 
have been implicated. Thioridazine, a drug 
which is reported to cause fewer extrapyra-
midal symptoms than other neuroleptics, 
does produce TD (Crane, 1975). Thus all 
drugs which can produce estrapyramidal 
signs can produce TD. However, the only 
neuroleptic which is reported not to pro-
duce parkinsonism and has the capacity 
of suppressing TD (Ayd, 1974) is Clozepine. 
Further confirmation of this claim is awaited. 
Animal experiments indicate that even the 
newer neuroleptic loxitane has the potential 
of producing TD (Sayers et al, 1975). 
Even though some studies indicate a corre-
lation between the duration of drug treat-
ment and the dosage and TD (Crane and 
Smeets 1974 ; Pryce and Edwards 1966; 
Crane, 1970) there are occasional reports of 
the occurrence of TD following exposure 
to small doses of phenothiazines for rela-
tively short periods of time (Evans, 1965 ; 
Simpson, 1973 ; Moline, 1975 ; Thorton 
and Thorton, 1973). In most patients TD 
makes an insiduous appearance while pa-
tients are still taking antipsychotic drugs 
(Degkwitz, 1969). However, it is frequently 
seen during the first four weeks of dosage 
reduction or withdrawal (Crane and Smeets, 
1974). 
Is dyskinesia reversible ? The terms per-
sistent dyskinesia and T. D. are used inter-
changeably thus creating semantic difficulty. 
If T. D. by definition is persistent, it has to 
be irreversible. However, such a state-
ment is only partially true. MacAndrews 
et al. (1972) found that drug-induced dys-
kinesia in children improved following drug 
withdrawal. Begkwitz (1969) reported 
that about 50 per cent of his TD patients 
became asymptomatic after several months 
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were under 50 years of age. Recovery 
rate seems to increase with the duration 
of follow up. Thus approximately 90 
percent of the patients in a six to 24 month 
follow up study (Crane, 1971) and almost 
all the patients in a 36 month follow up 
study (Haddenbrock, 1966) showed improve-
ment of their dyskinetic symptoms. Thus irre-
versibility is not absolute and many improve 
over time and only in some dyskinesia 
persists. In some, however, TD persists 
while in all patients after discontinuation 
of medication, the symptoms do not become 
worse. Some reports indicate that TD 
disappears in 19 to 40 percent of patients 
even on continued treatment (Marsden, 
et al., 1975 ; Kobayashi 1976). Based on 
this, Kline (1968) questioned whether the 
irreversibility of this syndrome had been 
adequately documented. Quitkin (1977) 
reported that when medication is with-
held upon the observation of early symp-
toms of TD, the syndrome is always revers-
ible. Therefore it is clear that many cases 
are reversible and some are probably treat-
ment-resistant. It is presumed that TD 
is irreversible based on the unproven as-
sumption of underlying irreversible brain 
damage or by conforming to the definition 
that TD is irreversible and excluding any-
thing that is reversible from the TD group. 
Instead of irreversible it is preferable to 
use the term treatment-resistant which will 
provide some optimism for searching new 
forms of therapy. 
CONCLUSIONS 
Tardive dyskinesia is a clinically dis-
tinct syndrome with characteristic involun-
tary movements, associated most often with 
the administration of neuroleptic drugs. 
As it can occur spontaneously as well as 
with the administration of other drugs, 
it is not a syndrome exclusive to neuro-
leptic therapy. 
The involuntary movements by the 
nature of their manifestations and by being 
iatrogenic and not disease related evoke 
attention of all the relatives as well as 
physicians. At one time considered irre-
versible, the same notion is still repeated 
by many recent workers perhaps by follow-
ing the definition that irreversibility is a 
characteristic of the syndrome and revers-
ibility is a criterion of exclusion. However, 
contrary to this notion, earlier cases are 
frequently reversible and even advanced 
cases may completely recover—unfortunately 
it is not possible to predict who would 
improve and who would not. The pre-
sumed organicity as an underlying patho-
genic mechanism is not borne out, thus 
providing optimism. With our current 
knowledge, to think in terms of irrevers-
ibility is definitely unwarranted and per-
haps one can call them treatment-resistant. 
With new developments they may all be 
reversible. 
TD does not seem to be as prevalent 
as the reported studies seem to indicate. 
These figures do not reflect either the new 
cases or all the cases of TD in a defined 
population over a fixed period of time. 
Thus they merely reflect the cumulative 
number of TD cases among the residual 
population of mental hospitals. These 
figures therefore may be higher than the 
actual prevalence or incidence. The figure 
of 3 to 6 percent suggested by the American 
College of Neuropsychopharmacology (1973) 
refers to those who would exhibit some 
aspects of TD at "one time or another". 
This seems to refer to "morbidity risk" 
which is many times higher than incidence. 
However, the symptoms are overt 
enough to be recognized easily and at the 
same time severe and incapacitating. How-
ever rare it is, as these are iatrogenic and 
treatment-resistant, certain clinical and legal 
implications need be considered. Should 
one be treating a patient with neuro-
leptics which can produce TD ? The answer 
is an unequivocal yes. The advantages 
of neuroleptics in treating acute as well 244  J. ANANTH 
as" long term psychotic patients far out-
weigh the risk. However, a minimal effect-
ive dose should be administered for mini-
mum length of time. Regarding main-
tenance therapy as Gardos and Cole (1976) 
have suggested, minimum dosage needed 
to prevent relapses be administered ; asymp-
tomatic patient who is fully functional 
should be allowed to discontinue medication 
if he so desires and be observed closely ; 
and in a dyskinetic patient medication 
should be completely withdrawn if the 
clinical state is compatible with such an 
action. Legally one could ask whether 
it is advisable to tell the patient of the 
possibility of the occurrence of TD. Or 
is it wise to withhold neuroleptics ? 
I cannot imagine myself explaining the 
side effects to a highly paranoid schizo-
phrenic and obtaining his full consent to 
treat. Furthermore, it is not even possible 
to predict who develops TD. Under these 
circumstances, it is not preferable to ex-
plain this side effect at least to acute schizo-
phrenic patients. 
This perhaps slightly exaggerated cur-
rent interest in TD may act as a catalyst 
to provide further clinical data and assist 
in treatment. 
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